These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38948439)

  • 1. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both.
    Wong R; Yuan LY
    World J Hepatol; 2024 Jun; 16(6):871-877. PubMed ID: 38948439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Singh A; Buckholz A; Kumar S; Newberry C
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Jul; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
    Henin G; Loumaye A; Leclercq IA; Lanthier N
    JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Sun M; Yao VJ; Rahman AA; Liu K; Rehman S; Sun A; Yao AC
    Cureus; 2024 May; 16(5):e61116. PubMed ID: 38919220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study.
    Son DH; Kwon YJ; Lee JH
    J Nutr Health Aging; 2024 Jun; 28(6):100270. PubMed ID: 38833877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.
    Kim MJ; Cho YK; Kim EH; Lee MJ; Lee WJ; Kim HK; Jung CH
    J Cachexia Sarcopenia Muscle; 2024 Jul; ():. PubMed ID: 39011807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
    Chen L
    World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
    Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
    Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping.
    Habib S
    World J Gastrointest Pathophysiol; 2024 May; 15(2):92791. PubMed ID: 38845820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms.
    Khanmohammadi S; Kuchay MS
    J Obes Metab Syndr; 2024 Jun; 33(2):108-120. PubMed ID: 38740429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.